Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varegacestat cardiac repolarization study in healthy volunteers
NCT06855264Phase 1Completed
- Sponsor
- Immunome
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of varegacestat (3 arms), sponsored by Immunome. Primary endpoint: Placebo-corrected change from baseline QTc at 24 hours. Started Feb 2025; status: completed.
02
Drugs
varegacestat
Beyond the preview
Go deeper on NCT06855264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855264.